The New Obesity Drugs: What Cardiac Practitioners Need to Know
Échec de l'ajout au panier.
Veuillez réessayer plus tard
Échec de l'ajout à la liste d'envies.
Veuillez réessayer plus tard
Échec de la suppression de la liste d’envies.
Veuillez réessayer plus tard
Échec du suivi du balado
Ne plus suivre le balado a échoué
The New Obesity Drugs: What Cardiac Practitioners Need to Know
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
Please join our special guest Dr. Ian Neeland from University Hospitals in Cleveland, to discuss the intersection of obesity and cardiovascular disease, and specifically the roles of the new agents semaglutide and tirzepatide. We discuss the recent data on cardiovascular outcomes with these agents, assessing patient candidacy, and tips for initiating and monitoring therapy. We also reviewed the complementary role of bariatric surgery and pharmacotherapy to improve cardiac outcomes.
For more information, see the SELECT study.
For more information about the UH CINEMA program, click on this link.
Please subscribe to receive updated episodes automatically! Visit https://www.ohioacc.org/cardiohio-podcast/.
“Upbeat Party” by scottholmesmusic.com
Pas encore de commentaire